ENVB

Enveric Biosciences Inc

Sep 16 • 04:00PM ET

0.9150

-0.0253 -2.69 %

Healthcare • Biotechnology • USA • NASD

Peers: CMPS AVXL CYBN SAVA ATAI MNMD RLMD GHRS NURO

Index	-	P/E	-	EPS (ttm)	-10.59	Insider Own	13.27%	Shs Outstand	3.03M	Perf Week	3.94%
Market Cap	2.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.82M	Perf Month	-16.82%
Enterprise Value	0.12M	PEG	-	EPS next Q	-	Inst Own	7.21%	Short Float	14.10%	Perf Quarter	-27.95%
Income	-9.94M	P/S	-	EPS this Y	-	Inst Trans	-7.01%	Short Ratio	1.98	Perf Half Y	-47.71%
Sales	0.00M	P/B	1.27	EPS next Y	-	ROA	-207.14%	Short Interest	0.40M	Perf YTD	-82.98%
Book/sh	0.72	P/C	1.04	EPS next 5Y	-	ROE	-261.96%	52W High	8.32 -89.01%	Perf Year	-87.80%
Cash/sh	0.88	P/FCF	-	EPS past 3/5Y	76.95% 57.47%	ROIC	-455.10%	52W Low	0.85 7.65%	Perf 3Y	-98.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.32% 9.05%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.53%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.28	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	73.88%	SMA20	-15.87%	Beta	0.65	Target Price	150.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-22.13%	Rel Volume	15.46	Prev Close	0.94
Employees	5	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	SMA200	-58.08%	Avg Volume	200.74K	Price	0.92
IPO	Aug 22, 1995	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,104,446	Change	-2.69%

Today 08:45AM	Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission (Business Wire)
Sep-03-25 08:30AM	Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-02-25 08:30AM	Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA (Business Wire)
Aug-28-25 08:30AM	Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications (Business Wire) -13.10%
Aug-14-25 08:00AM	Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results (Business Wire)
08:03AM	Loading…
Jul-23-25 08:03AM	Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series (Business Wire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-15-25 09:03AM	Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD) (Business Wire) -8.21%
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-24-25 09:03AM	Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 (Business Wire)
Jun-16-25 10:46AM	Enveric Biosciences Announces Participation in 2025 BIO International Convention (Business Wire)
Jun-10-25 09:03AM	Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders (Business Wire)
Jun-03-25 09:00AM	Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds (Business Wire)
May-29-25 09:10AM	Enveric Biosciences announces results from EB-003 trial (TipRanks)
May-28-25 09:03AM	Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 (Business Wire) -5.51%
08:00AM	Loading…
May-20-25 08:00AM	Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease (Business Wire)
May-14-25 04:15PM	Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results (Business Wire) -8.13%
Mar-31-25 08:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 (Business Wire) -5.44%
Mar-17-25 01:40PM	Enveric Biosciences Participating in BIO-Europe Spring (Business Wire)
Mar-07-25 10:05AM	Enveric Biosciences launches RFP solicitation process for PsyAI trademark (TipRanks) -5.21%
Mar-06-25 10:00AM	Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark (Business Wire) -8.57%
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks) +32.08%
Feb-27-25 09:30AM	Enveric Biosciences CEO Issues Letter to Shareholders (Business Wire) -7.83%
Feb-25-25 01:30PM	Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent (Business Wire) -13.87%
Feb-04-25 08:00AM	Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease (Business Wire)
Feb-03-25 05:00PM	Enveric Biosciences Announces Closing of $5 Million Public Offering (Business Wire) -13.40%
Jan-31-25 09:17AM	Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading (GuruFocus.com) -46.41%
Jan-30-25 08:14PM	Enveric Biosciences Announces Pricing of $5 Million Public Offering (Business Wire) -9.30%
04:01PM	Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office (Business Wire)
Jan-06-25 09:10AM	Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025" (Business Wire)
08:00AM	Loading…
Dec-02-24 08:00AM	Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds (Business Wire)
Nov-25-24 09:00AM	Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior (Business Wire)
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 04:05PM	Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results (Business Wire) -8.06%
Nov-12-24 09:00AM	Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 (Business Wire) -7.39%
Nov-04-24 10:36AM	Enveric Biosciences Announces Broad Range of Patent Issuances (Business Wire) -5.63%
Oct-15-24 08:00AM	Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 (Business Wire)
Sep-26-24 08:30AM	Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop (Business Wire) -5.78%
Sep-25-24 08:30AM	Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit (Business Wire) +7.14%
Sep-04-24 08:00AM	Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-13-24 08:00AM	Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries License for Treatment of Radiation Dermatitis and Other Conditions (Business Wire)
Aug-12-24 05:30PM	Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results (Business Wire)
Jul-25-24 08:00AM	Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally (Business Wire)
Jul-15-24 09:02AM	Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement (Business Wire)
Jul-10-24 08:00AM	Enveric Biosciences Announces Patent Granted for Drug Candidate (Business Wire) +5.82%
Jun-28-24 08:00AM	Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Jun-25-24 08:00AM	Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate (Business Wire) -7.29%
May-30-24 08:00AM	Enveric Biosciences to Participate in BIO International Convention 2024 (Business Wire)
May-20-24 11:54AM	ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:45AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-15-24 06:00AM	Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results (Business Wire)
May-14-24 08:00AM	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders (Business Wire)
May-08-24 07:00AM	Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids (Business Wire) +10.11%
May-02-24 05:50PM	Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks) +5.89%
Apr-12-24 12:00PM	What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock (Zacks) +10.95%
Apr-01-24 10:53AM	ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 (InvestorPlace) -11.00%
Mar-26-24 07:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 (Business Wire)
Mar-19-24 07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease (Business Wire) +8.18%
Mar-12-24 07:00AM	Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets (Business Wire) -9.09%
Feb-29-24 02:04PM	Why Is Enveric Biosciences (ENVB) Stock Up 120% Today? (InvestorPlace) +74.49%
07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds (Business Wire)
Feb-26-24 08:00AM	CORRECTION Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire) -13.12%
Feb-23-24 08:00AM	Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property (Business Wire) +15.29%
Feb-21-24 08:00AM	Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders (Business Wire)
Jan-03-24 08:00AM	Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire)
Dec-29-23 08:52AM	Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market (Business Wire) -16.67%
Dec-28-23 08:00AM	Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire) +19.77%
Dec-27-23 08:00AM	Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 (Business Wire)
Dec-20-23 08:00AM	Enveric Biosciences to Participate in Biotech Showcase 2024 During J.P. Morgan Week 2024 (Business Wire)
Dec-05-23 08:00AM	Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds (Business Wire) -5.10%
Nov-29-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives (Business Wire) +5.44%
Nov-27-23 08:00AM	Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry (Business Wire)
Nov-24-23 08:00AM	Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) (Business Wire)
Nov-13-23 04:01PM	Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results (Business Wire)
Oct-31-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin (Business Wire)
Oct-20-23 08:00AM	Enveric Biosciences to Present at the Centurion One 5th Global Summit (Business Wire) -5.45%
Oct-18-23 08:00AM	Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders (Business Wire)
Oct-11-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit (Business Wire) -8.04%
Oct-03-23 08:00AM	Enveric Biosciences Announces its Psybrary Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates (Business Wire) +20.00%
Sep-27-23 08:00AM	Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry (Business Wire) +7.94%
Sep-20-23 08:00AM	Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates (Business Wire) -6.45%
Sep-18-23 08:00AM	Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 (Business Wire)
Sep-11-23 08:00AM	Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives (Business Wire) +7.66%
Sep-05-23 08:00AM	Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives (Business Wire)
Aug-30-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference (Business Wire)
Aug-28-23 11:04AM	Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs (Business Wire) +7.41%
Aug-24-23 08:00AM	Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Aug-21-23 08:00AM	Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program (Business Wire) +7.44%
Aug-14-23 08:00AM	Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results (Business Wire)
Jul-24-23 08:00AM	Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 (Business Wire) -10.27%
Jul-17-23 08:00AM	Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 (Business Wire)
Jun-26-23 08:00AM	Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing (Business Wire) -5.84%
Jun-12-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire)
Jun-07-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) (Business Wire) -11.23%
Jun-05-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates (Business Wire)
May-30-23 08:00AM	Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 (Business Wire) -14.58%
May-24-23 08:00AM	Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug (Business Wire) +52.70%
May-22-23 08:00AM	Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders (Business Wire) -16.38%
May-19-23 08:00AM	Enveric Biosciences to Participate in 2023 BIO International Convention in Boston (Business Wire)
May-18-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin (Business Wire) +136.18%

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENVB

Enveric Biosciences Inc

Upgrade your FINVIZ experience